全文获取类型
收费全文 | 6810篇 |
免费 | 470篇 |
国内免费 | 51篇 |
专业分类
耳鼻咽喉 | 69篇 |
儿科学 | 125篇 |
妇产科学 | 108篇 |
基础医学 | 866篇 |
口腔科学 | 55篇 |
临床医学 | 745篇 |
内科学 | 1814篇 |
皮肤病学 | 94篇 |
神经病学 | 728篇 |
特种医学 | 243篇 |
外科学 | 950篇 |
综合类 | 51篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 374篇 |
眼科学 | 105篇 |
药学 | 436篇 |
中国医学 | 2篇 |
肿瘤学 | 564篇 |
出版年
2023年 | 36篇 |
2022年 | 26篇 |
2021年 | 128篇 |
2020年 | 97篇 |
2019年 | 144篇 |
2018年 | 192篇 |
2017年 | 124篇 |
2016年 | 138篇 |
2015年 | 177篇 |
2014年 | 228篇 |
2013年 | 326篇 |
2012年 | 544篇 |
2011年 | 523篇 |
2010年 | 315篇 |
2009年 | 307篇 |
2008年 | 466篇 |
2007年 | 505篇 |
2006年 | 421篇 |
2005年 | 476篇 |
2004年 | 479篇 |
2003年 | 401篇 |
2002年 | 370篇 |
2001年 | 66篇 |
2000年 | 61篇 |
1999年 | 51篇 |
1998年 | 65篇 |
1997年 | 63篇 |
1996年 | 42篇 |
1995年 | 60篇 |
1994年 | 51篇 |
1993年 | 39篇 |
1992年 | 42篇 |
1991年 | 36篇 |
1990年 | 20篇 |
1989年 | 26篇 |
1988年 | 20篇 |
1987年 | 23篇 |
1986年 | 19篇 |
1985年 | 20篇 |
1984年 | 16篇 |
1983年 | 16篇 |
1982年 | 10篇 |
1980年 | 15篇 |
1978年 | 12篇 |
1977年 | 14篇 |
1974年 | 13篇 |
1973年 | 12篇 |
1972年 | 9篇 |
1971年 | 14篇 |
1967年 | 8篇 |
排序方式: 共有7331条查询结果,搜索用时 171 毫秒
1.
Florent Le Ven François Pontana Gilles Barone-Rochette Laurent Macron Jérome Garot Olivier Genée Damien Mandry Luc Christiaens Alain Furber Jean Nicolas Dacher Alexis Jacquier 《Diagnostic and interventional imaging》2021,102(6):337-345
This position paper was intended to update the former consensus between the French Societies of Radiology and Cardiology about the use of stress cardiac magnetic resonance imaging (MRI) in chronic coronary syndrome published in 2009. The Delphi method was used to build the present consensus. This expert panel consensus includes recommendations for indications, procedure with patient preparation, stress inducing drugs, acquisition protocol, interpretation and risk stratification by stress MRI. 相似文献
2.
3.
4.
Eric Therasse Véronique Caty Patrick Gilbert Marie-France Giroux Pierre Perreault Louis Bouchard Vincent L. Oliva Jacques Lespérance Jean Ethier Georges Ouellet Martin Francoeur Serge Cournoyer Gilles Soulez 《Journal of vascular and interventional radiology : JVIR》2021,32(3):350-359.e2
PurposeTo assess whether angioplasty of hemodialysis access (HA) stenosis with a drug-coated balloon (DCB) would prevent restenosis in comparison with plain-balloon percutaneous transluminal angioplasty (PTA).Materials and MethodsThis prospective randomized clinical trial enrolled 120 patients with dysfunctional arteriovenous fistulae (n = 109) and grafts (n = 11), due to a ≥50% stenosis between March 2014 and April 2018. All patients underwent high-pressure balloon angioplasty and were then randomized to either DCB (n = 60) or PTA (n = 60). Patients were followed-up for 1 year, and angiography was performed 6 months after angioplasty. The primary endpoint was the late lumen loss (LLL) at 6 months. Secondary endpoints included other angiographic parameters at 6 months and HA failures, adverse event, and mortality at 12 months. Continuous variables were compared with a Student t-test, and Kaplan-Meier curves were used for freedom from HA failure and for mortality.ResultsLLL in the DCB and in the PTA group were 0.64 mm ± 1.20 and 1.13 mm ± 1.51, respectively (P = .082, adjusted P = .0498). DCB was associated with lower percentage stenosis (54.2% ± 19.3 vs 61.7% ± 18.2; P = .047) and binary restenosis ≥50% (56.5% vs 81.1%; P = .009) than PTA. The number of HA failures after 12 months was lower for DCB than for PTA (45% vs 66.7%; P = .017). Mortality at 12 months was 10% and 8.3% in the DCB and PTA groups, respectively (P = .75).ConclusionsDespite LLL improvement that failed to reach statistical significance, this study demonstrated decreased incidence and severity of restenosis with DCB compared with PTA to treat dysfunctional HA. 相似文献
5.
Emmanuelle Ranza Anne Guimier Alain Verloes Yline Capri Charles Marques Martine Auclair Michèle Mathieu-Dramard Gilles Morin Julien Thevenon Laurence Faivre Christel Thauvin-Robinet A. Micheil Innes David A. Dyment Corinne Vigouroux Jeanne Amiel 《Clinical genetics》2020,98(1):10-18
Overlapping syndromes such as Noonan, Cardio-Facio-Cutaneous, Noonan syndrome (NS) with multiple lentigines and Costello syndromes are genetically heterogeneous conditions sharing a dysregulation of the RAS/mitogen-activated protein kinase (MAPK) pathway and are known collectively as the RASopathies. PTPN11 was the first disease-causing gene identified in NS and remains the more prevalent. We report seven patients from three families presenting heterozygous missense variants in PTPN11 probably responsible for a disease phenotype distinct from the classical Noonan syndrome. The clinical presentation and common features of these seven cases overlap with the SHORT syndrome. The latter is the consequence of PI3K/AKT signaling deregulation with the predominant disease-causing gene being PIK3R1. Our data suggest that the phenotypic spectrum associated with pathogenic variants of PTPN11 could be wider than previously described, and this could be due to the dual activity of SHP2 (ie, PTPN11 gene product) on the RAS/MAPK and PI3K/AKT signaling. 相似文献
6.
Marcel Toussaint Raymond J. Gilles Noura Azzabou Benjamin Marty Alexandre Vignaud Andreas Greiser Pierre G. Carlier 《Medicine》2015,94(43)
Delayed contrast enhancement after injection of a gadolinium-chelate (Gd-chelate) is a reference imaging method to detect myocardial tissue changes. Its localization within the thickness of the myocardial wall allows differentiating various pathological processes such as myocardial infarction (MI), inflammatory myocarditis, and cardiomyopathies. The aim of the study was first to characterize benign myocarditis using quantitative delayed-enhancement imaging and then to investigate whether the measure of the extracellular volume fraction (ECV) can be used to discriminate between MI and myocarditis.In 6 patients with acute benign myocarditis (32.2 ± 13.8 year-old, subepicardial late gadolinium enhancement [LGE]) and 18 patients with MI (52.3 ± 10.9 year-old, subendocardial/transmural LGE), myocardial T1 was determined using the Modified Look-Locker Imaging (MOLLI) sequence at 3 Tesla before and after Gd-chelate injection. T1 values were compared in LGE and normal regions of the myocardium. The myocardial T1 values were normalized to the T1 of blood, and the ECV was calculated from T1 values of myocardium and blood pre- and post-Gd injection.In both myocarditis and MI, the T1 was lower in LGE regions than in normal regions of the left ventricle. T1 of LGE areas was significantly higher in myocarditis than in MI (446.8 ± 45.8 vs 360.5 ± 66.9 ms, P = 0.003) and ECV was lower in myocarditis than in MI (34.5 ± 3.3 vs 53.8 ± 13.0 %, P = 0.004).Both inflammatory process and chronic fibrosis induce LGE (subepicardial in myocarditis and subendocardial in MI). The present study demonstrates that the determination of T1 and ECV is able to differentiate the 2 histological patterns.Further investigation will indicate whether the severity of ECV changes might help refine the predictive risk of LGE in myocarditis. 相似文献
7.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
8.
9.
10.
Benoit Romain MD PhD Jean-Baptiste Delhorme MD PhD Gilles Manceau MD PhD Jérémie H Lefevre MD PhD Christophe Tresallet MD PhD Pascale Mariani MD Antonio Iannelli MD PhD Philippe Rouanet MD PhD Guillaume Piessen MD PhD Cécile Brigand MD PhD the AFC working group 《Journal of surgical oncology》2020,122(8):1639-1646